Stock Analysis
AbCellera Biologics Inc. (ABCL) Stock Analysis
AbCellera Biologics Inc. (ABCL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
AbCellera Biologics Inc. (ABCL) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 89/100. Risk is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ABCL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $11.49 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $3.65B |
| P/E Ratio (TTM) | -23.94 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.13 |
| Revenue (Q3 FY2026) | $10.64M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 2.42 |
| Volume | 2.68M |
| 52-week range | $2.75-$15.02 |
| RSI 14 | 45.24 |
| 50-Day SMA | $12.34 |
| 200-Day SMA | $7.24 |
| Analyst Price Target | $17.33 |
| Next Earnings | Feb 23, 2027 |
ABCLAbCellera Biologics Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum89
- Value47
- Quality61
- Risk resilience34
- Sentiment—
ABCL Stock Analysis Summary
AbCellera Biologics Inc. (ABCL) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 89/100. Risk resilience is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ABCL has AIQ Score of 64/100 with Momentum base of 89/100 and fading Risk resilience at 34/100. Wait for component alignment before adding exposure.
Momentum (89/100) leads while Risk resilience (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -1.12% stock move · ABCL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ABCL Bullish or Bearish Right Now?
ABCL currently has a neutral overall setup. Momentum is the strongest factor at 89/100, while Risk Resilience is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 89/100.
- - Analyst target implies +50.86% upside from the latest quote.
- - Value is the current constraint at 47/100.
- - Risk Resilience is weak at 34/100.
- - Technical consensus has more sell votes than buy votes (32 vs 7).
Current Consensus
ABCL's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 7 neutral, and 32 sell votes. ABCL's 14-day RSI is 45.24, which places the stock in a neutral momentum range. ABCL's beta is 2.42, indicating greater market sensitivity than the broad market.
What Changed in ABCL?
The largest recent change in ABCL is Quality moving up by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ABCL Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ABCL Decision Framework
Public evidence layers, setup checks, and risk context for AbCellera Biologics Inc..
AbCellera Biologics Inc. (ABCL) Stock Analysis
AbCellera Biologics Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 89/100. Beta is 2.42, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ABCL is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 89/100 while risk lags at 34/100. |
| Factor Evidence | Momentum 89/100 · Value 47/100 · Quality 61/100 · Risk 34/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 89/100.
Momentum is 89/100 and RSI (14) is 45.2.
ABCL is in a Neutral regime at 64/100.
Risk factor is 34/100 with beta 2.42 and annual volatility 85.28%.
Current conflict: momentum leads at 89/100 while risk lags at 34/100.
ABCL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ABCL Fundamentals
ABCL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ABCL Technical Analysis
ABCL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ABCL Stock Catalysts
Track ABCL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ABCL Dividend Analysis
ABCL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ABCL Financial Data
ABCL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ABCL Risk Analysis
ABCL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ABCL Stock News
ABCL stock news, market tone, recent headlines, and catalyst context.
ABCL vs Biotechnology Peers
Current peer cohort: ABCL · ABSI · ABUS · ABVX · ADMA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ABCL Current stock | 64/100 | 47/100 | 89/100 | 34/100 | 1.73 | 85.28% | Current |
| ABSI Absci Corporation | 53/100 | — | 85/100 | 30/100 | 1.58 | 104.15% | ABCL vs ABSI |
| ABUS Arbutus Biopharma Corp | 70/100 | 92/100 | 51/100 | 62/100 | -0.09 | 45.89% | ABCL vs ABUS |
| ABVX Abivax S.A. | 35/100 | — | 34/100 | 37/100 | 0.24 | 86.44% | ABCL vs ABVX |
| ADMA ADMA Biologics, Inc. | 78/100 | 80/100 | 91/100 | 56/100 | -0.01 | 58.93% | ABCL vs ADMA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ABCL: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ABCL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ABCL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ABCL Stock FAQ
What is ABCL stock price today?
AbCellera Biologics Inc.'s current stock price is $11.49. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ABCL bullish or bearish right now?
ABCL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ABCL's market cap?
ABCL's market cap is $3.65B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ABCL's current P/E ratio?
ABCL's current P/E ratio is -23.94 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ABCL's RSI?
ABCL's 14-day RSI is 45.24 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ABCL above its 50-day and 200-day moving averages?
ABCL is -6.86% from its 50-day SMA and 58.77% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ABCL's next earnings date?
ABCL's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ABCL pay a dividend?
ABCL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.